metricas
covid
Buscar en
Gastroenterología y Hepatología
Toda la web
Inicio Gastroenterología y Hepatología Helicobacter pylori y factores inmunogenéticos del huésped: relevancia de los ...
Journal Information
Vol. 24. Issue 3.
Pages 117-121 (January 2001)
Share
Share
Download PDF
More article options
Vol. 24. Issue 3.
Pages 117-121 (January 2001)
Full text access
Helicobacter pylori y factores inmunogenéticos del huésped: relevancia de los alelos HLADQA1*0102 y *0301 en la úlcera péptica
Helicobacter Pylori And Inmunogenetic Host Factors: Role Of The *0102 And *0301 Alleles In Peptic Ulcer Disease
Visits
3911
S. Santolariaa,
Corresponding author
ssantolariap@medynet.com

Correspondencia: Dr. S. Santolaria. Servicio de Aparato Digestivo. Hospital Universitario de Canarias. 38291 La Laguna. Tenerife.
, Y. Barriosb, R. Benitoc, E. Piazueloa, E. Quinterob, A. Lanasa
a Servicios de Aparato Digestivo Hospital Clínico Universitario de Zaragoza
b Servicios de Microbiología. Hospital Clínico Universitario de Zaragoza
c Servicio de Aparato Digestivo. Hospital Universitario de Canarias. La Laguna. Tenerife
This item has received
Article information
Objetivo

Investigar la potencial contribución de los alelos *0102 y *0301 del gen HLADQA1 en la infección por H. pylori y la enfermedad ulcerosa péptica en una población caucásica española.

Pacientes y Métodos

Se incluyeron un total de 163 pacientes con úlcera péptica (117 úlcera duodenal [UD] y 46 úlcera gástrica [UG]; 111 con hemorragia digestiva alta reciente) y 90 controles. Los alelos *0102 y *0301 del gen HLADQA1 se tipificaron mediante PCR a partir de ADN genómico. La infección por H. pylori se determinó en los pacientes mediante test de aliento y/o histología y en los controles por test de aliento y/o serología. En 98 pacientes y en 48 controles con infección por H. pylori se investigaron las citotoxinas CagA y VacA mediante serología (Western-blot).

Resultados

La infección por H. pylori estaba presente en el 94,6% de UD, el 84,4% de UG y el 67,4% de los controles (p < 0,001). El alelo *0102 del gen HLADQA1 presentó una distribución similar en pacientes (31,9%) y controles (36,7%). El alelo *0301 fue más frecuente en el grupo de UG (32,6%) con respecto a la UD (16,2%) (p < 0,05), pero no se observaron diferencias cuando se comparó con el grupo control (24,4%). Tampoco se encontraron diferencias cuando se analizaron los grupos de acuerdo con la presencia de infección por H. pylori, cepas CagA y VacA positivas, consumo de antiinflamatorios no esteroides o historia previa ulcerosa o de hemorragia

Conclusiones

Ser portador de los alelos *0102 y *0301 del gen HLADQA1 no modifica ni la susceptibilidad a la infección por H. pylori ni su evolución a úlcera péptica en una población caucásica del sur de Europa.

Aim

To investigate the potential contribution of the *0102 and *0301 alleles of the HLADQA1 gene in Helicobacter pylori infection and peptic ulcer disease in a Spanish Caucasian population.

Patients and Methods

We studied 163 patients with peptic ulcer (117 duodenal ulcers and 46 gastric ulcers; 111 with recent upper gastrointestinal hemorrhage) and 90 controls. The *0102 and *0301 alleles of the HLADQA1 gene were typed by polymerase chain reaction using genomic DNA. H. pylori infection were determined by breath test and/or serology. The cytotoxins CagA and VacA were investigated using serology (Western-blot) in 98 patients and 48 controls with H. pylori infection.

Results

H. pylori infection was found in 94.6% of patients with duodenal ulcer, in 84.4% of those with gastric ulcer and in 67.4% of controls (p < 0.001). The distribution of the *0102 allele of the HLADQA1 gene was similar in patients (31.9%) and in controls (36.7%). The *0301 was more frequent in patients with gastric ulcer (32.6%) than in those with duodenal ulcer (16.2%) (p < 0.05) but no differences were found on comparison with the control group (24.4%). No differences were found when the groups were analyzed according to H. pylori infection, CagA-and VacA-positive strains, consumption of non-steroidal antiinflammatory drugs or previous history of ulcer or hemorrhage.

Conclusion

The *0102 and *0301 alleles of the HLADQA1 gene did not alter susceptibility to H. pylori infection or the evolution of peptic ulcer disease in a Caucasian population in Spain.

Full text is only aviable in PDF
Biblografía
[1.]
B.J. Marshall.
The 1995 Albert Lasker Medical Research Award. Helicobacter pylori. The etiologic agent for peptic ulcer.
JAMA, 274 (1995), pp. 1064-1066
[2.]
S. Censini, C. Lange, Z. Xiang, J.E. Crabtree, P. Ghiara, M. Borodovsky, et al.
Cag, a pathogenicity island of Helicobacter pylori, encodes type I-specific and disease-associated virulence factors.
Proc Natl Acad Sci USA, 93 (1996), pp. 14648-14653
[3.]
I.L.P. Beales, J.E. Crabtree, D. Scunes, A. Covacci, J. Calam.
Antibodies to CagA protein are associated with gastric atrophy in Helicobacter pylori infection.
Eur J Gastroenterol Hepatol, 8 (1996), pp. 645-649
[4.]
L.J. Van Doorn, C. Figueiredo, R. Sanna, A. Plaisier, P. Schneeberger, W. De Boer, et al.
Clinical relevance of the CagA, VacA, and IceA status of Helicobacter pylori.
Gastroenterology, 115 (1998), pp. 58-66
[5.]
J.C. Atherton, R.M.J. Peek, K.T. Tham, T.L. Cover, M.J. Blaser.
Clinical and pathological importance of heterogeneity in VacA, the vacuolating cytotoxin gene of Helicobacter pylori.
Gastroenterology, 112 (1997), pp. 92-99
[6.]
S. Maeda, K. Ogura, H. Yoshida, F. Kanai, T. Ikenoue, N. Kato, et al.
Major virulence factors, VacA and CagA, are commonly positive in Helicobacter pylori isolates in Japan.
Gut, 42 (1998), pp. 338-343
[7.]
H.M. Malaty, L. Engstrand, N.L. Pedersen, D.Y. Craham.
Helicobacter pylori infection: genetic and environmental influences: a study of twins.
Ann Intern Med, 120 (1994), pp. 349-352
[8.]
I. Räihä, H. Kemppainen, J. Kaprio, M. Koskenvuo, L. Sourander.
Lifestyle, stress, and genes in peptic ulcer disease. A nationwide twin cohort study.
Arch Intern Med, 158 (1998), pp. 698-704
[9.]
M.F. Go.
What are the host factors that place an individual at risk for Helicobacter pylori-associated disease?.
Gastroenterology, 113 (1997), pp. S15-S20
[10.]
R.D. Campbell, T. Trowsdale.
Map of the human MHC.
Immunol Today, 14 (1993), pp. 349-352
[11.]
A. Wee, M. Teh, J.Y. Kang.
Association of Helicobacter pylori with HLA-DR antigen expression in gastritis.
J Clin Pathol, 45 (1992), pp. 30-33
[12.]
M. Chiba, N. Ishii, T. Ishioka, M. Murata, O. Masamune, T. Sugiyama, et al.
Topographic study of Helicobacter pylori and HLADR antigen expression on gastric epithelium.
J Gastroenterol, 30 (1995), pp. 149-155
[13.]
A. Ihan, I. Krizman, V. Ferlan-Marolt, B. Tepez, M. Gubina.
HLA-DR expression on CD8 lymphocytes from gastric mucosa in urease-positive and urease-negative gastritis.
FEMS Immunol Med Microbiol, 10 (1995), pp. 295-299
[14.]
T. Azuma, J. Konishi, Y. Tanaka, M. Hirai, S. Ito, T. Kato, et al.
Contribution of HLA-DQA gene to host's response against Helicobacter pylori [carta].
Lancet, 343 (1994), pp. 542-543
[15.]
T. Azuma, Y. Ito, H. Miyaji, M. Dojyo, Y. Tanaka, M. Hirai, et al.
Immunogenetic analysis of the human leukocyte antigen DQA1 locus in patients with duodenal ulcer or chronic atrophic gastritis harbouring Helicobacter pylori.
Eur J Gastroenterol Hepatol, 7 (1995), pp. S71-S73
[16.]
T. Azuma, J. Konishi, Y. Ito, M. Hirai, Y. Tanaka, S. Ito, et al.
Genetic differences between duodenal ulcer patients who were positive or negative for Helicobacter pylori.
J Clin Gastroenterol, 21 (1995), pp. S151-S154
[17.]
T. Azuma, S. Ito, F. Sato, Y. Yamazaki, H. Miyaji, Y. Ito, et al.
The role of the HLA-DQA1 gene in resistance to atrophic gastritis and gastric adenocarcinoma induced by Helicobacter pylori infection.
Cancer, 82 (1998), pp. 1013-1018
[18.]
O. Olerup, A. Aldener, A. Fogdell.
HLA-DQB1 and BDQA1 typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours.
Tissue Antigens, 41 (1993), pp. 119-134
[19.]
M. Larrea, Y. Barrios, A. Jiménez, E. Salido, E. Quintero.
Interaction between host HLA-DQB1 and Helicobacter pylori genotype predicts the development of peptic ulcer disease [resumen].
Gastroenterology, 116 (1996), pp. A232
[20.]
J.E. Lee, A.M. Lowy, W.A. Thompson, M. Lu, P.T. Loflin, J.M. Skibber, et al.
Association of gastric adenocarcinoma with the HLA Class II gene DQB1*0301.
Gastroenterology, 111 (1996), pp. 426-432
[21.]
A. Lanas, M.A. García-González, B.A. Crusius, S. Santolaria, M.T. Serrano, A.S. Peña.
Helicobacter pylori and NSAID induced gastric and duodenal ulcers are associated with polymorphisms of the TNF genes [resumen].
Gastroenterology, 114 (1998), pp. A1.018
[22.]
E.M. El-Omar, M. Carrington, W.H. Chow, K.E. McColl, J.H. Bream, H.A. Young, et al.
Interleukin-1 polymorphisms associated with increased risk of gastric cancer.
Nature, 404 (2000), pp. 398-402
[23.]
J. Karhukorpi, I. Ikäheimo, S. Sivennoinen-Kassinen, S. Tiilikainen, R. Karttunen.
HLA-DQA1 alleles and the presence of Helicobacter pylori antibodies.
Eur J Immunogenet, 26 (1999), pp. 15-17
[24.]
B. Martínez-Jarreta, M. Bolea, M. Castellano, R. Hinojal, E. Abecia.
Distribution of HLA DQA1 alleles and genotypes in two Spanish populations (Aragón and Asturias).
Forensic Science International, 81 (1996), pp. 185-190
[25.]
J.I. Rotter, G.M. Petersen, I.M. Samloff.
Pepsinogens and other physiologic markers in genetic studies of peptic ulcer and related disorders.
Prog Clin Biol Res, 173 (1985), pp. 227-244
[26.]
H.O. Hein, P. Suadicani, F. Gyntelberg.
Genetic markers for peptic ulcer. A study of 3387 men aged 54 to 74 years: the Copenhagen Male Study.
Scand J Gastroenterol, 32 (1997), pp. 16-21
[27.]
S. Miehlke, M.F. Go, J.G. Kim, D.Y. Graham, N. Figura.
Serologic detection of Helicobacter pylori infection with cagA-positive strains in duodenal ulcer, gastric cancer, and asymptomatic gastritis.
J Gastroenterol, 33 (1998), pp. 18-21
Copyright © 2001. Elsevier España, S.L.. Todos los derechos reservados
Download PDF
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos